Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy

Cancer Treatment Reviews

Volumn 28, Issue 4, 2002, Pages 189-194

  Dreicer, Robert ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hormonal therapy; PSA recurrence

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CANCER VACCINE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SULINDAC SULFONE;

ADVANCED CANCER; ANEMIA; ANTIGEN DETECTION; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG TOLERABILITY; FATIGUE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIBIDO DISORDER; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; MUSCLE DISEASE; ORCHIECTOMY; PHYSICIAN; POTENCY DISORDER; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; TREATMENT FAILURE;

EID: 0036669114     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00046-4     Document Type: Article

References (51)

1. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276: 1309-1315.
2. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. Cancer 1998; 83: 1679-1684.
3. Burkhardt JH, Litwin MS, Rose CM, et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 2002; 20: 2869-2875.
4. Soulie M, Villers A, Grosclaude P, et al. Cancer of the prostate in France: Results of the survey CCAFU-FRANCIM. Prog Urol 2001, 11: 478-485.
5. Amling CL, Blute ML, Bergstralh EJ, et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101-105.
6. Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406.
7. Dillioglugil O, Leibman BD, Kattan MW, et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997; 50: 93 97.
8. Savage P, Bates C, Abel P, et al. British urological survey practice: 1. Prostate cancer. Br J Urol 1997; 79: 754-755.
9. Laufer M, Pound CR, Carducci MA, et al. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000; 55: 309-315.
10. Walsh PC, Deweese TL, Eisenberger M. A structured debate: Immediate vs. deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2001; 166: 508-516.
11. Sylvester J, Grimm P, Blasco J, et al. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: A survey of practice patterns of urologists and radiation oncologists in the US. Urology 2001; 58: 65-70.
12. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
13. Cher ML, Bianco Jr. FJ, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate-specific antigen elevations after radical prostatectomy. J Urol 1998; 160: 1387-1391.
14. Kramer S, Gorich J, Gottfried HW, et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997; 70: 995-999.
15. 111indium-labeled Cyt-356 for the detection of occult prostate cancer recurrence. J Urol 1994; 152:1490-1494.
16. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998; 159: 2041-2046.
17. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111-capromab pendetide. Cancer 1998; 83: 739-747.
18. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium-111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94: 987-996.
19. Wasson JH, Fowler FJ, Barry MJ. Androgen-deprivation therapy for asymptomatic advanced prostate cancer in the prostate-specific antigen era: A national survey of urologist beliefs and practicies. J Urol 1998; 159: 1993-1997.
20. Blackard CE, Byar DP, Jordan WP. Orchiectomy for advanced prostatic carcinoma: A reevaluation. Urology 1973; 1: 553-560.
21. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-1130.
22. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
23. MV P, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of radiation therapy oncology group protocol 85-31. J Clin Oncol 1997; 15: 1013-1021.
24. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen-deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
25. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1789.
26. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate vs. deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235-246.
27. Schroder FH. Endocrine treatments of prostate cancer: Recent developments and the future. Part I: Maximal androgen blockade, early vs. delayed endocrine treatment and side-effects. BJU Int 1999; 83: 107-161.
28. Kirk D. RE: A structured debate: Immediate vs. deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2002; 167: 651-652.
29. Kirk D. Immediate vs. deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Medical Research Council. Prostate cancer working party investigators group. BJU 2000;(suppl 86): 220.
30. Walsh PC, Deweese TL, Eisenberger M. RE: A structured debate: Immediate vs. deferred androgen suppression in prostate cancer-evidence for deferred treatment. Reply by authors. J Urol 2002; 167: 653.
31. Carroll PR, Lee KL, Fuks ZY, et al. Cancer of the prostate. In: Devita VT, Hellman S, Rosenberg SA (eds.), Cancer Principles and Practice of Oncology. Lippincott Williams and Wilkins: Philadelphia, 2001; 1463.
32. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen-deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186.
33. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-1222.
34. Hatano T, Oishi Y, Fututa A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. BJU Int 2000; 86: 449-452.
35. Smith MR, Mcgovern FJ, Zietman AI, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
36. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with non-metastatic prostate cancer on androgen-deprivation therapy. J Urol 2000; 163: 1743-1746.
37. Anderson J. Quality of life aspects of treatment options for localized and locally advanced prostate cancer. Eur Ural 2001; 40: 24-30.
38. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389-396.
39. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy vs. castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-456.
40. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-577.
41. Dawson NA. Intermittent androgen deprivation. Curr Oncol Rep 2000; 2: 409-416.
42. Rennie PS, Bruchovsky N, Coldman AJ. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J Steroid Biochem Mol Biol 1990; 37: 843-847.
43. Furuya Y, Sato N, Akakura K, et al. Paracrine growth stimulation of androgen-responsive Shionogi Carcinoma 115 by its autonomous subline (Chiba Subline 2). Cancer Res 1990; 50: 4979-4983.
44. Gleave M, Bruchovsky N, Goldenberg SL, et al. Intermittent androgen suppression for prostate cancer: Rationale and clinical experience. Eur Urol 1998; 34: 37-41.
45. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time of therapy. Oncologist 2000; 5: 45-52.
46. Grossfeld GD, Chaudhary UB, Reese DM, et al. Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001; 58: 240-245.
47. American Society For Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-1041.
48. Amling CL, Bergstralh EJ, Blute ML, et al. Defining prostate-specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 2001; 165: 1146-1151.
49. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II Clinical Trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J Clin Oncol 1999; 17: 3461-3467.
50. Eisenberger MA, Nelson W. How much can we rely on the level of prostate-specific antigen as an end-point for evaluation of clinical trials? A word of caution. J Natl Cancer Inst 1996; 88: 779-781.
51. Goluboff ET, Prager D, Rukstalis D, et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 2001; 166: 882-886.